Emerging drugs in the management of hypertension

Expert Opinion on Emerging Drugs

Volumn 8, Issue 2, 2003, Pages 377-388

  Whitworth, Judith A ^a  

^a Australian National University   (Australia)

Author keywords

Aldosterone receptor antagonists; Angiotensin II receptor antagonists; Blood pressure; Calcium antagonists; Cardiovascular risk; Centrally acting drugs; Combination therapy; Endothelin receptor antagonists; Hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; EFONIDIPINE; HYDRALAZINE; LERCANIDIPINE; LISINOPRIL; METHYLDOPA; MINOXIDIL; NEBIVOLOL; PROSTACYCLIN DERIVATIVE; RENIN INHIBITOR; RESERPINE; TEMOCAPRIL; THROMBOXANE RECEPTOR BLOCKING AGENT; UNINDEXED DRUG; VALSARTAN; VASODILATOR AGENT; VASOPEPTIDASE INHIBITOR; VERAPAMIL;

ANGIONEUROTIC EDEMA; CLINICAL PRACTICE; CONSTIPATION; COUGHING; DEPRESSION; DIURETIC THERAPY; DRUG STRUCTURE; EDEMA; FLUSHING; HEADACHE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; IMPOTENCE; ORTHOSTATIC HYPOTENSION; PHARMACOGENOMICS; POTASSIUM DEFICIENCY; REVIEW; SEDATION; SIDE EFFECT; SODIUM RETENTION; TACHYCARDIA; WATER RETENTION;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS;

EID: 0345735916     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.8.2.377     Document Type: Review

References (80)

1. NO AUTHORS LISTED: The World Health Report 2002, Reducing Risks, Promoting Healthy Life. World Health Organisation, Geneva (2002).
2. COLLINS AJ, LI S, MA SZ, HERZOG C: Cardiovascular disease in end-stage renal patients. Am. J. Kidney Dis. (2001) 38:S26-S29.
3. YUSEF S, SLEIGHT P, POGUE J, BOSCH J, DAVIES R, DEGENAIS G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. (2000) 342:145-153.
4. DAGKIF B, DEVEREUX RB, KJELDSEN SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359:995-1003.
5. STAESSEN JA, WANG JG, THYS L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet (2001) 358:1305-1315.
6. NEAL B, MACMAHON S, CHAPMAN N: Effects of ACE inhibitors, calcium antagonists and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists Collaboration. Lancet (2000) 356:1955-1964.
7. COLLINS R, PETO R, MACMAHON S, HERBERT P, FIEBACH NH, EBERLEIN KA: Blood pressure, stroke and coronary heart disease, Part 2 Short term reductions in blood pressure: overview of randomized drug trials in their epidemiologic context. Lancet (1990) 335:827-838.
8. JAFAR TH, SCHMID CH, LANDA M et al: Angiotensin-converting enzyme inhibitors and progression of non-diabetic renal disease. A meta-analysis of patient-level data. Am. Intern. Med. (2001) 135:138-139.
9. NO AUTHORS LISTED: Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDA 38 UK Prospective. Diabetes Study Group. Br. Med. J. (1998) 317:703-713.
10. NO AUTHORS LISTED: Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. ALLHAT Collaborative Research Group. JAMA (2002) 288:298-299.
11. CHALMERS J, MCMAHON S, MANCIA G et al.: 1999 World Health Organisation-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J. Hypertens. (1999) 17:151-183.
12. NO AUTHORS LISTED: Randomized trial of a perindopril based regimen on blood pressure lowering among 6105 individuals with previous stroke or transient ischaemic attack. Progress Collaborative Group. Lancet (2001) 358:1003-1041.
13. TURNER ST, BOERWINKLE E: Genetics of blood pressure, hypertensive complications and anti-hypertensive drug responses. Pharmacogenomics (2003) 4:53-65.
14. WELTON PK, HE J, APPEL LJ et al.: Primary prevention of hypertension: Clinical and public health advisory from the National High Blood Pressure Education Program. JAMA (2002) 288:1882-1888
15. NO AUTHORS LISTED: Bibliography Current World Literature: pathophysiology of hypertension. Curr. Opin. Nephrol. Hypertens. (2003) 12:212-20.
16. ERDINE S: How well is hypertension controlled in Europe? J. Hypertens. (2000) 18:1348-1349.
17. GU D, REYNOLDS K, WU X et al: Prevalence, awareness, treatment, and control of hypertension in China. InterASIA Collaborative Group. Hypertension (2002) 40:920-927.
18. RUDOLPH AE, MCMAHON EG: Emerging therapies for heart failure. Expert Opin. Emerging Drugs (2002) 7:247-258.
19. PHILLIPS MI: Gene therapy for hypertension: the preclinical data. Methods Enzymol. (2002) 346:3-13.
20. TURNER ST, SCHWARTZ GL, CHAPMAN AB, HALL WD, BOERWINKLE E: Antihypertensive pharmacogenetics: getting the right drug in the right patient. J. Hypertens. (2001) 19:1-11.
21. STOSCHITZKY K, LINDNER W, KIOWSKI W: Stereoselective vascular effects of the (R)- and (S)-enantiomers of propranolol and atenolol. J. Cardiovasc. Pharmacol. (1995) 25:268-272.
22. IGNARRO LJ, BYRNS RE, TRINH K, SISODIA M, BUGA GM: Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms. Nitric Oxide (2002) 7:75-82.
23. MAZZA A, GIL-EXTREMERA B, MALDONATO A, TOUTOUZAS T, PESSINA AC: Nebivolol versus amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press. (2002) 11:182-188.
24. MESSERLI FH: Evolution of calcium antagonists: past, present, and future. Clin. Cardiol. (2003) 26:II12-II16.
25. MESSERLI FH: Calcium antagonists in hypertension: from hemodynamics to outcomes. Am. J. Hypertens. (2002) 15:94S-97S.
26. ZANCHETTI A: Emerging data on calcium-channel blockers: the COHORT study. Clin. Cardiol. (2003) 26:II17-II20.
27. LEONETTI G, MAGNANI B, PESSINA AC, RAPPELLI A, TRIMARCO B, ZANCHETTI A: Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. COHORT Study Group. Am J. Hypertens. (2002) 15:932-940.
28. ZHANG H: Clevidipine (the Medicines Company). Curr. Opin. Investig. Drugs (2002) 3:1474-1478.
29. SCHWIELER JH, ERICSSON H, LOFDAHL P, THULIN T, KAHAN T: Circulatory effects and pharmacology of devidipine, a novel ultra short acting and vascular selective calcium antagonist, in hypertensive humans. J. Cardiovasc. Pharmacol. (1999) 34:268-274.
30. LIAU CS, CHIEN KL, CHAO CL, LEE TM: Efficacy and safety of barnidipine compared with feldopine in the treatment of hypertension in Chinese patients. J. Int. Med. Res. (2002) 30:330-336.
31. MALHOTRA HS, PLOSKER GL: Barnidipine. Drugs (2001) 61:989-996.
32. OHMORI M, ARAKAWA M, HARADA K et al.: Stereoselective pharmacokinetics of amlodipine in elderly hypertensive patients. Am. J. Ther. (2003) 10:29-31.
33. HARADA K, NOMURA M, NISHIKADO A, UEHARA K, NAKAYA Y, ITO S: Clinical efficacy of efonidipine hydrochloride, a T-type calcium channel inhibitor, on sympathetic activities. Circ. J. (2003) 67:139-145.
34. HAYASHI K, KUMAGAI H, SARUTA T: Effect of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am. J. Hypertens. (2003) 16:116-122.
35. BLACK HR, ELLIOTT WJ, GRANDITS G et al: Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA (2003) 289:2073-2082.
36. SMITH DH, NEUTEL JM, WEBER MA: A new chronotherapeutic oral drug absorption system for verapamil optimizes blood pressure control in the morning. Am. J. Hypertens. (2001) 14:14-19.
37. HANSSON L, HEDNER T, LUND-JOHANSEN P et al.: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet (2000) 356:359-365.
38. SONG JC, WHITE CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin. Pharmacokinet. (2002) 41:207-224.
39. LEWIS E, HUNSIKER L, CLARKE W et al.: Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. (2001) 345:815-860.
40. BRENNER B, COOPER ME, DE ZEEUW D et al.: Effects of Losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. (2001) 345:861-869.
41. BISWAS PN, WILTON LV, SHAKIR SW: The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England. J. Hum. Hypertens. (2002) 16:795-803.
42. GARDNER SF, FRANKS AM: Olmesartan medoxomil: the seventh angiotensin receptor antagonist. Ann. Pharmacother. (2003) 37:99-105.
43. MESSERLI F: Moxonidine: a new and versatile antihypertensive. J. Cardiovasc. Pharmacol. (2000) 35:S53-S56.
44. SZABO B: Imidazoline antihypertensive drugs: a critical review on their mechanism of action. Pharmacol. Ther. (2002) 93:1-35.
45. DOGGRELL SA: Moxonidine: some controversy. Expert Opin. Pharmacother. (2001) 2:337-350.
46. DELYANI JA, ROCHA R, COOK CS et al: Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc. Drug Rev. (2001) 19:185-200.
47. WEINBERGER MH, RONIKER B, KRAUSE SL, WEISS RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. (2002) 15:709-716.
48. KRUM H, NOLLY H, WORKMAN D et al.: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension (2002) 40:I17-I23.
49. FLACK JM, OPARIL S, PRATT JH et al.: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J. Am. Coll. Cardiol. (2003) 41:1148-1155.
50. NEUTEL JM, SMITH DH: Improving patient compliance: a major goal in the management of hypertension. J. Clin. Hypertens. (2003) 5:127-132.
51. LACOURCIERE Y: A new fixed-dose combination for added blood pressure control: telmisartan plus hydrochlorothiazide. J. Int. Med. Res. (2002) 30:366-379.
52. NEUTEL JM, KOLLOCH RE, PLOUIN PF, MEINICKE TW, SCHUMACHER H: Telmisartan versus losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension - a randomised ABPM study. J. Hum. Hypertens. (2003) 17:569-575.
53. SCHMIDT A, ADAM SA, KOLLOCH R, WEIDINGER G, HANDROCK R: Antihypertensive effects of valsartan/hydrochlorothiazide combination in essential hypertension. Blood Press. (2001) 10:230-237.
54. KOCHAR M, GUTHRIE R, TRISCARI J, KASSLER-TAUB K, REEVES RA: Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am. J. Hypertens. (1999) 12:797-805.
55. MELIAN EB, JARVIS B: Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. Drugs (2002) 62:787-816.
56. SACHSE A, VERBOOM CN, JAGER B: Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J. Hum. Hypertens. (2002) 16:169-176.
57. COATS AJ: Omapatrilat-the story of Overture and Octave. Int. J. Cardiol. (2002) 86:1-4.
58. BARTON M, KIOSWKI W: The therapeutic potential of endothelin receptor antagonists in cardiovascular disease. Curr. Hypertens. Rep. (2001) 3:322-330.
59. DOGGRELL SA: The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system. Expert Opin. Investig. Drugs (2002) 11:1537-1552.
60. KRUM H, VISKOPER RJ, LACOURCIERE Y, BUDDE M, CHARLON V: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N. Engl. J. Med. (1998) 338:784-790.
61. NAKOV R, PFARR E, EBERLE S: Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. HEAT Investigators. Am. J. Hypertens. (2002) 15:583-589.
62. SERRADEIL-LE GAL C, WAGNON J, VALETTE G et al.: Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog. Brain Res. (2002) 139:197-210.
63. MCLAUGHLIN VV, GAINE SP, BARST RJ et al.: Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. Treprostinil Study Group. J. Cardiovasc. Pharmacol. (2003) 41:293-299.
64. FINK AN, FRISHMAN WH, AZIZAD M, AGARWAL Y: Use of prostacydin and its analogues in the treatment of cardiovascular disease. Heart Dis. (1999) 1:29-40.
65. OHMORI M, KITOH Y, KAWAGUCHI A, HARADA K, SUGIMOTO K, FUJIMURA A: Enhanced neutrophil superoxide anion production and its modification by beraprost sodium in spontaneously hypertensive rats. Am. J. Hypertens. (2001) 14:722-728.
66. STANTON A: Potential of renin inhibition in cardiovascular disease. J. Renin. Angiotensin Aldosterone Syst. (2003) 4:6-10.
67. ALLIKMETS K: Aliskiren (Speedel). Curr. Opin. Investig. Drugs (2002) 3:1479-1482.
68. NUSSBERGER J, WUERZNER G, JENSEN G, BRUNNER HR: Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension (2002) 39:E1-E8.
69. GALIPEAU D, ARIKAWA E, SEKIROV I, MCNEILL JH: Chronic thromboxane synthase inhibition prevents fructose-induced hypertension. Hypertension (2001) 38:872-876.
70. SUGIMOTO KI, SHIGA T, FUJIMURA A: Delayed hypotensive effect of the thromboxane A2/prostaglandin H2 receptor antagonist S-1452 in spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. (2000) 27:594-600.
71. ROSENFELD L, GROVER GJ, STIER CT JR: Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist. Cardiovasc. Drug Rev. (2001) 19:97-115.
72. LEVY PJ, YUNIS C, OWEN J, BROSNIHAN KB, SMITH R, FERRARIO CM: Inhibition of platelet aggregability by losartan in essential hypertension. Am. J. Cardiol. (2000) 86:1188-1192.
73. O'CONNELL DP, AHERNE AM: Renal dopaminergic mechanisms and hypertension: a chronology of advances. Clin. Exp. Hypertens. (2000) 22:217-249.
74. SANADA H, ASICO LD, SHIGETOMI S et al.: The effect of docarpamine, a dopamine pro-drug, on blood pressure and catecholamine levels in spontaneously hypertensive rats. Clin. Exp. Hypertens. (2000) 22:419-429.
75. BEHRENDS S: Drugs that activate specific nitric oxide sensitive guanylyl cyclase isoforms independent of nitric oxide release. Curr. Med. Chem. (2003) 10:291-301.
76. FERRANDI M, BARASSI P, MINOTTI E et al.: PST 2238: a new antihypertensive compound that modulates renal Na-K pump function without diuretic activity in Milan hypertensive rats. J. Cardiovasc. Pharmacol. (2002) 40:881-889.
77. SCHONER W: Endogenous cardiac glycosides, a new class of steroid hormones. Eur. J. Biochem. (2002) 269:2440-2448.
78. KAPLAN NM: Should new drugs be used without outcome data? Implications of ALLHAT and Elite II. Arch. Intern. Med. (2001) 161:511-512.
79. CHANG M, HAHN RA, TEUTSCH SM, HUTWAGNER LC: Multiple risk factors and population attributable risk for ischemic heart disease mortality in the United States, 1971-1992. J. Clin. Epidemiol. (2001) 54:634-644.
80. LEWINGTON S, CLARKE R, QIZILBASH N, PETO R, COLLINS R: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaborative. Lancet (2002) 360:1903-1913.